ArticleACS applied nano materials2026
Iridium Nanoparticle-Gated Janus Nanomachines for Enzyme-Controlled Drug Delivery.
Article in ACS applied nano materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Controlled drug delivery systems (DDSs) have emerged as a promising alternative to conventional therapies, aiming to optimize drug release profiles and improve therapeutic outcomes while reducing systemic side effects. In this work, iridium-gated Janus nanomachines are proposed as enzyme-regulated platforms for smart and autonomous drug delivery. These hybrid nanostructures consist of mesoporous silica nanoparticles asymmetrically functionalized with gold nanoparticles bearing surface-anchored enzymes on the metallic hemisphere, while the opposite mesoporous face incorporates pH-responsive molecular gates based on aminophenylboronic acid and d-lactose-functionalized iridium nanoparticles, enabling efficient cargo loading and motility behavior. To evaluate nanomachine operation, two enzymatic systems were employed: glucose oxidase (GOx) and a tandem esterase/alcohol oxidase (AOX) system, using spectrophotometric monitoring of the model cargo release. Both platforms exhibited well-defined release kinetics and good correlation between substrate concentration and high selectivity toward their respective inputs. Motility studies revealed the appearance of two particle populations in the presence of glucose or methanol, consistent with enhanced motion driven by catalytic reactions at the iridium nanoparticle surface upon enzymatic hydrogen peroxide generation. Finally, the GOx-based nanomachine loaded with the antitumoral drug doxorubicin (DOXO) demonstrated efficient cellular internalization, preserved biocompatibility, and enhanced antitumoral activity in HeLa cells. Overall, this work reinforces the potential of enzyme-controlled Janus nanomachines as multifunctional platforms integrating autonomous motion and stimulus-responsive drug delivery for advanced therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.